Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
1999-04-07
2010-10-26
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S449000
Reexamination Certificate
active
07820718
ABSTRACT:
This invention provides a method for increasing apoptosis in tumor cells and a method of decreasing a size of a tumor, said methods comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone. This invention also provides a method of treating cancer in a subject which comprises a method according to either of the above-described methods. This invention provides a method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly. This invention provides a pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and at least one ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5478860 (1995-12-01), Wheeler
patent: 5631394 (1997-05-01), Wei et al.
patent: 6465448 (2002-10-01), Gerson et al.
patent: 6664288 (2003-12-01), Pardee et al.
patent: 6841537 (2005-01-01), Joshi et al.
patent: WO94/04541 (1994-03-01), None
Mycek, et al. “Lippincott's Illustrated Reviews: Pharmacology, 2nd ed.” 1997, Lippincott-Raven Pub. p. 376, 391-392.
Hartfield PJ et al. “Ceramide induces apoptosis in PC12 cells,” 1997 FEBS Letters vol. 401, pp. 148-152.
Cai Z et al., “Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma . . . ,” 1997 J Biological Chemistry 272(11): 6918-6926.
Spencer CM and Faulds D, “Paclitaxel. A review of its pharmacodynamis and pharmacokinetic properties and therapeutic potential in the treatment of cancer,” 1994 Drugs 48(5): 794-847.
Cecil Textbook of Medicine, 21st Edition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074.
BASF, “Cremophor® EL” Technical Leaflet [online], Jul. 1997; retrieved on Nov. 3, 2005 from the internet <<http://www2.zzu.edu.cn/syzx/lijx/cremophorel.pdf >>.
Baselga, J. et al. (1997) “HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications,”Oncol. Mar. 11 (3 suppl 2), 43-48. (Exhibit 1).
Jayadev, S. et al. (1995) “Role for ceramide in cell cycle arrest,”J. Biol. Chem. 270(5): 2047-2052. (Exhibit 2).
Mathias, S. et al. (1998) “Signal transduction of stress via ceramide,”Biochem. J. 335:465-480. (Exhibit 3).
Perez, E. A. et al. (1998) “Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines,”Cancer Chemother. Pharmacol. 41(6): 448-452. (Exhibit 4).
Shirahama, T. et al. (1997) “In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosin in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells,”Clin. Cancer Res. 3:257-264. (Exhibit 5).
Ping SE. Barrett GL. “Ceramide can induce cell death in sensory neurons, whereas ceramide analogues and sphingosine promote survival”,J Neurosci Res. vol. 54, No. 2, Oct. 15, 1998, pp. 206-213 (Exhibit B).
Myrick, D., et al., “Taxol and ceramide act synergistically in the growth inhibition of Jurkat, a leukemic T-cell line”,Faseb Journal, vol. 11, No. 2, p. A546 (Abstract, 1997).
Myrick, D.C., et al., “Paclitaxel-induced apoptosis in Jurkat, a leukemic T-cell, is enhanced by ceramide”,FASEB Journal, vol. 13, No. 4, Part 1, p. A191 (Abstract, Mar. 12, 1999).
Myrick, Dorkina, et al., “Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide”,Leukemia Research, vol. 23, No. 6, pp. 569-578 (Jun. 1999).
Mehta Shashikant
Wanebo Harold J.
Anderson James D
Cooper & Dunham LLP
Roger Williams Hospital
White John P.
LandOfFree
Combinations of ceramide and chemotherapeutic agents for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of ceramide and chemotherapeutic agents for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of ceramide and chemotherapeutic agents for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177082